Australia markets close in 5 hours 23 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
292.80+0.39 (+0.13%)
At close: 04:00PM EDT
292.90 +0.10 (+0.03%)
After hours: 07:59PM EDT

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees3,900

Key executives

NameTitlePayExercisedYear born
Dr. Jeffrey Marc Leiden M.D., Ph.D.Exec. Chairman281.98kN/A1956
Dr. Reshma Kewalramani FASN, M.D.CEO, Pres & Director4.27MN/A1973
Mr. Charles F. Wagner Jr.Exec. VP & CFO1.85MN/A1968
Mr. Stuart A. Arbuckle B.Sc.Exec. VP & COO2.56M197.69k1966
Dr. Ourania Tatsis Ph.D.Exec. VP and Chief Regulatory & Quality Officer1.33MN/A1971
Ms. Kristen C. AmbroseChief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. ServicesN/AN/A1977
Dr. David M. Altshuler M.D., Ph.D.Exec. VP of Global Research & Chief Scientific OfficerN/AN/A1965
Mr. Mike TirozziSVP and Chief Information & Data OfficerN/AN/AN/A
Mr. Michael PartridgeSr. VP of Investor RelationsN/AN/AN/A
Mr. Damian W. Wilmot Esq.Sr. VP, Chief Risk and Compliance OfficerN/AN/A1976
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Corporate governance

Vertex Pharmaceuticals Incorporated’s ISS governance QualityScore as of 1 September 2022 is 7. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.